The reiteration of an Overweight rating and maintenance of a $140 price target by a reputable analyst like Louise Chen from Cantor Fitzgerald could positively influence investor sentiment towards Novo Nordisk. This endorsement reaffirms confidence in the company's future performance and growth prospects, likely leading to a positive short-term impact on the stock price.